Your Treatment Is ‘Waiting on Prior Authorization’: What That Means and What You Can Do
Waiting on Prior Authorization: What It Means for Your Care
It usually means your eye doctor has recommended a treatment, such as an injection for your retina, and your health plan wants to review and approve it before it will agree to pay. Under prior authorization, your provider submits a request and receives the plan's decision before the service is given1. Your treatment is not denied; it is paused in a paperwork step. This page explains what the step is, why it can cause delay, what you can do to move it along, and the point at which a delay itself becomes a medical concern worth a same-day call.
Three things help most: ask your eye doctor's office to confirm the request was submitted and to give you a reference number; ask what the plan is waiting for and whether a peer-to-peer call or appeal is planned; and watch your vision closely. Because gaps and undertreatment with anti-VEGF injections have been linked to worse visual outcomes, an authorization limbo should not quietly become an untreated eye2. If your vision changes while you wait, that changes the urgency, and we cover exactly when to call below.
What Prior Authorization Is and Why It Causes Delays
Prior authorization is a cost-control and coverage-check step that many Medicare Advantage and commercial plans apply to higher-cost treatments, including some retina injections. The plan reviews whether the treatment meets its coverage rules and is medically necessary before the service is provided, and only then issues a decision1. The review takes staff time on both sides and can add days, sometimes a week or two, before treatment begins.
This surprises many people. An approved prior authorization gives some assurance of payment, but it does not guarantee final payment, because your eligibility and the plan's medical-necessity rules still apply when the claim is processed1. In practice that means an approval is a green light to proceed, not a signed check. Your eye doctor's billing office can tell you what your expected share of the cost would be under your specific plan once the treatment is authorized.
Some delays come from a rule called step therapy, or 'fail first.' A plan may require the use of a preferred, usually lower-cost injection such as bevacizumab before it will cover a higher-cost drug such as aflibercept3. This does not mean the preferred drug is wrong for you; for many eyes it works well. If a step-therapy policy is not followed, the resulting claim denial may not carry the same appeal rights, so it is worth clarifying the rule up front3.
Whether Your Treatment Is Likely to Qualify
Most authorizations turn on whether the record clearly shows the treatment is medically necessary. Prior authorization approval generally turns on medical necessity, which is why complete documentation from your eye doctor is central1. For retina injections that usually means the diagnosis, imaging such as an OCT scan, and the clinical reason this specific drug and schedule were chosen. You do not assemble this yourself; your eye doctor's office does, but knowing what matters helps you ask useful questions.
Step therapy is more likely when your doctor has requested a higher-cost drug as a first choice. If your retina specialist prefers a particular anti-VEGF agent for clinical reasons, such as your prior response or a specific disease pattern, ask that the reasoning be documented in your record, since it can support a request for an exception. Ask your office whether your plan has a step-therapy rule for your treatment and, if so, whether they are requesting the preferred drug or an exception.
This page is for someone whose recommended eye treatment is stuck in a plan's review. It explains the process and your options; it does not tell you which drug you should receive or predict your coverage, because that depends on your diagnosis, your plan, and your eye doctor's judgment. Use it to have a sharper conversation with the office handling your case, not to replace that conversation.
Working With Your Eye Doctor's Office to Move It Forward
A few direct questions often shorten a delay. Confirm the request was actually submitted and get the date and a reference number. Ask what the plan is waiting for, whether anything is missing, and how long the plan has to respond. Ask who in the office owns your authorization so you have one contact. Keep your own short log of dates, names, and what you were told; it is invaluable if the case has to be escalated or appealed.
If the plan hesitates or denies, your doctor's office has tools you do not. One is a peer-to-peer review, where your eye doctor speaks directly with a physician at the plan to explain medical necessity. Failure to obtain a required prior authorization leads to a rejected claim, so having the office complete or appeal the authorization before treatment matters3. Ask whether a peer-to-peer call or a formal appeal is the next step, and what you can do to support it.
You are not only a bystander here. If a plan denies coverage, it must tell you why, and you have the right to an internal appeal; if it stays denied, you can request an external review by an independent third party4. Deadlines apply, so read any denial letter promptly and act within the stated window.
When an Authorization Delay Becomes a Reason to Call Now
Paperwork can wait; your eye may not. Call your eye doctor's office promptly, and ask to be seen, if while you are waiting you notice:
- A sudden drop or new blur in your vision
- A new dark spot, curtain, or shadow in your sight
- A sudden increase in floaters or new flashes of light
- Straight lines that look bent or wavy, or new distortion
- Pain, redness, or worsening after a recent injection
These can signal that the condition your treatment is meant to control is progressing, which is a clinical question, not an insurance one. If you cannot reach your eye doctor and your vision loss is sudden and severe, seek urgent eye care rather than waiting on the authorization.
The reason a delay is worth taking seriously is medical, not administrative. Anti-VEGF injections can prevent vision loss in conditions such as wet age-related macular degeneration, and because they control rather than cure the disease, treatment is typically ongoing on a schedule5. In real-world care, undertreatment and less frequent anti-VEGF injections have been linked to worse visual outcomes than the more regular schedules used in clinical trials2. That is why an open authorization deserves active follow-up rather than passive waiting.
Keep your existing appointments, take your other eye medications as prescribed, and do not assume the delay means the treatment was refused. Ask the office whether they can schedule the treatment provisionally so you are ready the moment approval lands. If cost is your worry, ask about the drug manufacturer's patient-assistance programs and any nonprofit copay help, which your office or a social worker can point you toward.
Common Questions About Prior Authorization Delays
It varies by plan and by whether the request is routine or urgent, from a day or two to a couple of weeks. If a denied claim is appealed and your case is urgent, your insurance company must speed up that appeal review4. Ask your eye doctor's office to flag the request as urgent when your vision is at risk, and to tell you the plan's required decision timeframe so you know when to follow up.
You can, but talk to the billing office first. Retina injections and the drugs themselves can be expensive, and paying privately may not count toward your deductible or be refundable if the plan later approves the treatment. In many cases pursuing the authorization or an expedited appeal is both cheaper and fast enough. Reserve out-of-pocket payment for situations where your eye doctor says the timing is genuinely urgent and approval cannot come fast enough.
No. A denial is a decision you can challenge, not a final verdict. A denied plan decision can be appealed internally and, if still denied, taken to an independent external review that the insurer no longer controls4. Many denials are overturned when the medical necessity is documented, or resolved by switching to a plan-preferred drug that works just as well for your eye. Your doctor's office can tell you which path fits your case.
That is step therapy, a cost-control rule. A plan may require a preferred, lower-cost injection such as bevacizumab before covering a higher-cost option such as aflibercept3. For many eyes the preferred drug controls the disease well, so trying it is often reasonable. If your eye doctor believes a different drug is needed for your specific situation, that clinical reasoning can support a request for an exception.
More Questions About Appeals, Costs, and Your Role
Keep a simple record: the date the request was submitted, the reference or case number, the names of people you spoke with, what each said, and any deadlines on letters you receive. If you get a denial, note the reason given and the appeal deadline. This log turns a frustrating black box into something you and your doctor's office can act on, and it is exactly what an appeal or external review will need.
Not exactly. An approval provides some assurance of payment but is not a guarantee, because eligibility and medical-necessity rules still apply when the claim is finalized1. Think of it as clearing the main hurdle rather than crossing the finish line. Your billing office can estimate your out-of-pocket share once the treatment is authorized under your specific plan and benefit year.
Often, yes. The office controls the documentation the plan reviews and can request a peer-to-peer discussion or file an appeal on clinical grounds. A required prior authorization that is not obtained results in a rejected claim, so the office completing and, if needed, appealing the request is central to getting your treatment covered3. Your job is to keep the office moving and to report any vision changes promptly so urgency can be conveyed to the plan.
- Has my authorization been submitted, and what is the reference number and date?
- Does my plan have a step-therapy rule, and are we requesting the preferred drug or an exception?
- Can this be marked urgent, and what is the plan's required decision timeframe?
- If it is denied, will you do a peer-to-peer review or file an appeal, and how can I help?
- What vision changes should make me call you right away while I wait?
- Centers for Medicare & Medicaid Services (CMS) (2024). Prior Authorization and Pre-Claim Review Initiatives.
- Retina Today (2021). Long-Term Outcomes of Anti-VEGF Therapy.
- Retina Today (2021). Why Was My Intravitreal Injection Claim Denied?.
- HealthCare.gov (U.S. Centers for Medicare & Medicaid Services) (2024). Appealing a health plan decision: Internal appeals and external review.
- American Academy of Ophthalmology (EyeSmart) (2024). What's the Difference Between Avastin, Eylea and Lucentis?.